An Open-label, Multicenter, Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym013, a mAb Mixture Targeting EGFR, HER2 and HER3, in Patients With Advanced Epithelial Malignancies

Trial Profile

An Open-label, Multicenter, Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym013, a mAb Mixture Targeting EGFR, HER2 and HER3, in Patients With Advanced Epithelial Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Sep 2017

At a glance

  • Drugs Monoclonal antibodies (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Symphogen
  • Most Recent Events

    • 29 Jun 2017 Dose of PAN-Her has increased from 2 to 4,number of arms has changed from 3 to 6,hence patient number also changed from 75 to 130.
    • 22 Jun 2017 Planned number of patients changed from 75 to 131.
    • 22 Jun 2017 Planned End Date changed from 1 Oct 2019 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top